Less than a decade on from genetic studies indicating the potential of PCSK9 as a target to affect cholesterol metabolism, two PCSK9 inhibitors are moving into late-stage development.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Sauchinone controls hepatic cholesterol homeostasis by the negative regulation of PCSK9 transcriptional network
Scientific Reports Open Access 30 April 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. Cholesterol-lowering blockbuster candidates speed into Phase III trials. Nat Rev Drug Discov 11, 817–819 (2012). https://doi.org/10.1038/nrd3879
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3879
This article is cited by
-
Sauchinone controls hepatic cholesterol homeostasis by the negative regulation of PCSK9 transcriptional network
Scientific Reports (2018)
-
Redefining the role of biomarkers in heart failure trials: expert consensus document
Heart Failure Reviews (2017)
-
Validating therapeutic targets through human genetics
Nature Reviews Drug Discovery (2013)
